These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 11981076)

  • 1. Daily haemodialysis improves indices of protein glycation.
    Floridi A; Antolini F; Galli F; Fagugli RM; Floridi E; Buoncristiani U
    Nephrol Dial Transplant; 2002 May; 17(5):871-8. PubMed ID: 11981076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis.
    Fagugli RM; Vanholder R; De Smet R; Selvi A; Antolini F; Lameire N; Floridi A; Buoncristiani U
    Int J Artif Organs; 2001 May; 24(5):256-62. PubMed ID: 11420874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis.
    Fragedaki E; Nebel M; Schupp N; Sebekova K; Völkel W; Klassen A; Pischetsrieder M; Frischmann M; Niwa T; Vienken J; Heidland A; Stopper H
    Nephrol Dial Transplant; 2005 Sep; 20(9):1936-43. PubMed ID: 15919695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds.
    Henle T; Deppisch R; Beck W; Hergesell O; Hänsch GM; Ritz E
    Nephrol Dial Transplant; 1999 Aug; 14(8):1968-75. PubMed ID: 10462279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients.
    Stein G; Franke S; Mahiout A; Schneider S; Sperschneider H; Borst S; Vienken J
    Nephrol Dial Transplant; 2001 May; 16(5):999-1008. PubMed ID: 11328907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites.
    Klemm A; Franke C; Busch M; Müller A; Franke S; Lang D; Passlick-Deetjen J; Stein G
    Clin Nephrol; 2004 Mar; 61(3):191-7. PubMed ID: 15077870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of an increase in time vs. frequency on cardiovascular parameters in chronic hemodialysis patients.
    Weinreich T; De los Ríos T; Gauly A; Passlick-Deetjen J
    Clin Nephrol; 2006 Dec; 66(6):433-9. PubMed ID: 17176915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic analysis of furosine and pentosidine in CAPD patients.
    Kumano K; Yokota S; Sakai T; Kobayashi N; Yoshida A; Yoshihara T; Shibata K; Izumi G; Wang H
    Adv Perit Dial; 1997; 13():53-7. PubMed ID: 9360651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality.
    Gerdemann A; Wagner Z; Solf A; Bahner U; Heidland A; Vienken J; Schinzel R
    Nephrol Dial Transplant; 2002 Jun; 17(6):1045-9. PubMed ID: 12032195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodialysis techniques and advanced glycation end products.
    Tessitore N; Lapolla A; Aricó CN; Gammaro L; Bernich P; Fedele D
    Contrib Nephrol; 2001; (131):33-9. PubMed ID: 11125561
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy.
    Suliman ME; Stenvinkel P; Jogestrand T; Maruyama Y; Qureshi AR; Bárány P; Heimbürger O; Lindholm B
    Clin Nephrol; 2006 Dec; 66(6):418-25. PubMed ID: 17176913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy.
    Miyata T; Ueda Y; Yoshida A; Sugiyama S; Iida Y; Jadoul M; Maeda K; Kurokawa K; van Ypersele de Strihou C
    Kidney Int; 1997 Mar; 51(3):880-7. PubMed ID: 9067925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients.
    Slowick-Zylka D; Safranow K; Dziedziejko V; Dutkiewicz G; Ciechanowski K; Chlubek D
    J Nephrol; 2006; 19(1):65-9. PubMed ID: 16523428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy.
    Raj DS; Lim G; Levi M; Qualls C; Jain SK
    Am J Kidney Dis; 2004 Jan; 43(1):154-60. PubMed ID: 14712439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.
    Makita Z; Bucala R; Rayfield EJ; Friedman EA; Kaufman AM; Korbet SM; Barth RH; Winston JA; Fuh H; Manogue KR
    Lancet; 1994 Jun; 343(8912):1519-22. PubMed ID: 7911868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.
    Misselwitz J; Franke S; Kauf E; John U; Stein G
    Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sensitive and specific ELISA for plasma pentosidine.
    Izuhara Y; Miyata T; Ueda Y; Suzuki D; Asahi K; Inagi R; Sakai H; Kurokawa K
    Nephrol Dial Transplant; 1999 Mar; 14(3):576-80. PubMed ID: 10193802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels.
    Tessitore N; Lapolla A; Aricò NC; Poli A; Gammaro L; Bassi A; Bedogna V; Corgnati A; Reitano R; Fedele D; Lupo A
    J Nephrol; 2004; 17(5):707-14. PubMed ID: 15593039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The advanced glycation endproduct pentosidine and monocyte activation in uremia.
    Friedlander MA; Witko-Sarsat V; Nguyen AT; Wu YC; Labrunte M; Verger C; Jungers P; Descamps-Latscha B
    Clin Nephrol; 1996 Jun; 45(6):379-82. PubMed ID: 8793229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy.
    Suliman ME; Heimbürger O; Bárány P; Anderstam B; Pecoits-Filho R; Rodríguez Ayala E; Qureshi AR; Fehrman-Ekholm I; Lindholm B; Stenvinkel P
    J Am Soc Nephrol; 2003 Jun; 14(6):1614-22. PubMed ID: 12761263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.